Customer Appreciation Sale.
15% off with promo code "APPRECIATION2023" on check out or purchase order
- Yuki Shimizu, .et al. Acquired resistance to BRAF inhibitors is mediated by BRAF splicing variants in BRAF V600E mutation-positive colorectal neuroendocrine carcinoma, Cancer Lett, 2022, Sep 1;543 PMID: 35724767
- Yajun Li, .et al. Urolithin B suppressed osteoclast activation and reduced bone loss of osteoporosis via inhibiting ERK/NF-??B pathway, Cell Prolif, 2022, Oct;55(10) PMID: 35708050
- Sergey A. Dyshlovoy, .et al. Activity of New Synthetic (2-Chloroethylthio)-1,4-naphthoquinones in Prostate Cancer Cells, Pharmaceuticals, 2021, 14(10), 949
- Sergey A Dyshlovoy, .et al. Marine alkaloid monanchoxymycalin C: a new specific activator of JNK1/2 kinase with anticancer properties, Sci Rep, 2020, Aug 6;10(1):13178 PMID: 32764580
- Guo X, .et al. PDGF-induced migration of synthetic vascular smooth muscle cells through c-Src-activated L-type Ca2+ channels with full-length CaV1.2 C-terminus, Pflugers Arch, 2018, Jun;470(6):909-921 PMID: 29441404
- Takuya Hasegawa, .et al. ErbB2 signaling epigenetically suppresses microRNA-205 transcription via Ras/Raf/MEK/ERK pathway in breast cancer, FEBS Open Bio, 2017, Aug; 7(8): 1154-1165 PMID: 28781955
Biological Activity
SCH772984 is a novel, specific inhibitor of ERK1/2 with IC50 of 4 nM and 1 nM, respectively.
Targets
ERK2 (Cell-free assay) | ERK1 (Cell-free assay) | MEK1 (Cell-free assay) | ||
1 nM | 4 nM | >10 μM |
In vitro (25°C) | DMSO | Warmed: 13 mg/mL (22.12 mM) | |
Water | Insoluble | ||
Ethanol | Insoluble | ||
In vivo | 5% DMSO+30% PEG 300+ddH2O | 0.5 mg/mL | |
* <1 mg/ml means slightly soluble or insoluble. * Please note that Adooq tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. |
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
0.1 mM | 17.02 mL | 85.08 mL | 170.16 mL |
0.5 mM | 3.4 mL | 17.02 mL | 34.03 mL |
1 mM | 1.7 mL | 8.51 mL | 17.02 mL |
5 mM | 0.34 mL | 1.7 mL | 3.4 mL |
*The above data is based on the productmolecular weight 587.68. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
Catalog Num | A12824 |
---|---|
Actions | Inhibitor |
CAS No. | 942183-80-4 |
Formula | C33H33N9O2 |
M. Wt | 587.68 |
Purity | >98% |
Synonyms | SCH-772984, SCH 772984 |
SMILES | C1CN(C[[email protected]@H]1C(=O)NC2=CC3=C(C=C2)NN=C3C4=CC=NC=C4)CC(=O)N5CCN(CC5)C6=CC=C(C=C6)C7=NC=CC=N7 |
Storage | Store lyophilized at -20ºC, keep desiccated. |
Product Tags
Product Questions
Product Questions
No Questions
You may also be interested in the following product(s)
PD98059
PD98059 is an equipotent antagonist of the aryl hydrocarbon receptor and inhibitor of mitogen-activated protein kinase kinase.
TCS ERK 11e (VX-11e)
TCS ERK 11e (VX-11e) is a potent and selective extracellular signal-related kinase 2 (ERK2) inhibitor (Ki values are
PD 334581
PD 334581 is used in biological studies to evaluate halogen bonding as a novel interaction for rational drug design. It is also an inhibitor…
AZD8330
AZD8330 is a novel, selective, non-ATP competitive MEK 1/2 inhibitor with IC50 of 7 nM. Phase 1.
Refametinib
Refametinib is a potent, ATP non-competitive and highly selective inhibitor of MEK1 and MEK2 with IC50 of 19 nM and 47 nM, respectively.
PD0325901
PD0325901 is MEK inhibitor and non-competitive with ATP, Kiapp of 1 nM against activated MEK1 and MEK2.
MEK162 (ARRY-438162, Binimetinib)
MEK162 (ARRY-438162) is a potent, selective, ATP uncompetitive inhibitor of MEK1/2.
GDC-0623
GDC-0623 is a potent and ATP-uncompetitive MEK1 inhibitor with Ki of 0.13 nM. Phase 1.
Keywords:buy SCH772984 | SCH772984 Supplier | purchase | cost | manufacturer | order | distributor | buy 942183-80-4| 942183-80-4 Supplier | purchase 942183-80-4 | 942183-80-4 cost | 942183-80-4 manufacturer | order 942183-80-4 | 942183-80-4 distributor